Abstract
Since the Framingham Heart Study solidified cholesterol as a causative agent in the development of coronary heart disease there has been an explosion of research in the field of lipidology. Many therapeutic options have come and gone as we have been refining the goals of therapy to match the mortality outcome data of large clinical trials. A new frontier has emerged with the introduction of the PCSK9 inhibitors that are able with monthly injections to lower LDL cholesterol >60% with favorable side effect profiles and recently published favorable mortality data. This ushers in a whole new era of cholesterol management. Life insurance medical directors will need to be informed of how these drugs are being used and for conditions such as homozygous hypercholesterolemia, a condition with a very high mortality risk, and for new genetic analysis of affected patients, who are not as rare as once thought. This article provides the background about the development of these drugs, their expanded indications, how they may slip through the cracks of prescription drug (Rx) database inquiries, and touches on therapies in development beyond this class of medications. Medicine is an evolving field. With the new gene editing CRISPR technology i...Continue Reading
References
Jun 18, 2002·Journal of Cellular and Molecular Medicine·C Stancu, A Sima
Jan 29, 2003·Proceedings of the National Academy of Sciences of the United States of America·Nabil G SeidahMichel Chretien
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Aug 24, 2004·American Journal of Epidemiology·Melissa A AustinSteve E Humphries
Jan 18, 2005·Nature Genetics·Jonathan CohenHelen H Hobbs
Mar 24, 2006·The New England Journal of Medicine·Jonathan C CohenHelen H Hobbs
Sep 23, 2006·Atherosclerosis·Amanda J HooperJohn R Burnett
Jul 14, 2010·Current Atherosclerosis Reports·Jean DavignonNabil G Seidah
Sep 29, 2011·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G TibollaA L Catapano
Mar 20, 2012·The Journal of Clinical Investigation·Ding AiAlan R Tall
Aug 21, 2013·European Heart Journal·Børge G NordestgaardUNKNOWN European Atherosclerosis Society Consensus Panel
Jul 24, 2014·European Heart Journal·Marina CuchelUNKNOWN European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia
Jan 21, 2015·Basic Research in Cardiology·Rainer SchulzUlrich Laufs
Feb 6, 2015·Nature Medicine·David Benjamin Turitz CoxFeng Zhang
Mar 16, 2017·World Journal of Cardiology·Rahul ChaudharyAndrew Sumner
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Mar 18, 2017·The New England Journal of Medicine·Kausik K RayJohn J P Kastelein
Apr 25, 2017·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Paul S JellingerMichael Davidson
May 24, 2017·Journal of Clinical Lipidology·Carl E OrringerJames A Underberg
Aug 17, 2017·The New England Journal of Medicine·Robert P GiuglianoUNKNOWN EBBINGHAUS Investigators
Oct 2, 2017·Journal of Clinical Lipidology·Joep C DefescheJohn J P Kastelein
Nov 14, 2017·Hepatology Communications·Linda OmerNolan L Boyd